Breaking News, Collaborations & Alliances

Novartis Acquires Chinese Biotech SanReno Therapeutics

Gains two late-stage assets targeting Immunoglobulin A Nephropathy (IgAN) with exclusive rights in greater China and Singapore.

SanReno Therapeutics, a clinical-stage company specializing in the discovery, development, and commercialization of therapies for kidney diseases, has been acquired by Novartis. SanReno will become an indirect, wholly owned subsidiary of Novartis. SanReno holds exclusive rights in greater China and Singapore for two late-stage assets targeting Immunoglobulin A Nephropathy (IgAN): atrasentan and zigakibart. Atrasentan, an oral endothelin A receptor antagonist (ERA), is in Phase 3 development f...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters